Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-AC-02 in Alzheimer's Disease
NCT02899091Phase 2Active, not recruiting
- Sponsor
- CHA Biotech
- Start
- Sep 2016
- Primary completion
- Dec 2024
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CB-AC-02 in Alzheimer's disease (AD), sponsored by CHA Biotech. Started Sep 2016; status: active, not recruiting.
02
Drugs
CB-AC-02
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02899091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02899091.